Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
Maurice J D L van der VorstElisabeth C W NeefjesManon S A BoddaertBea A T T VerdegaalAart BeekerSaskia C C TeunissenAartjan T F BeekmanJanneke A WilschutJohannes BerkhofWouter W A ZuurmondHenk M W VerheulPublished in: The oncologist (2019)
Guidelines recommend that pharmacological interventions for delirium treatment in adults with cancer should be limited to patients who have distressing delirium symptoms. It was suggested that atypical antipsychotics, such as olanzapine, outperform haloperidol in efficacy and safety. However, collective data comparing the efficacy and safety of typical versus atypical antipsychotics in patients with cancer are limited. If targeted and judicious use of antipsychotics is considered for the treatment of delirium in patients with advanced cancer, this study demonstrated that there was no statistically significant difference in response to haloperidol or olanzapine. Olanzapine showed an overall better safety profile compared with haloperidol, although this difference was not statistically significant.
Keyphrases
- advanced cancer
- palliative care
- cardiac surgery
- phase iii
- randomized controlled trial
- squamous cell carcinoma
- physical activity
- open label
- hip fracture
- acute kidney injury
- newly diagnosed
- combination therapy
- big data
- artificial intelligence
- young adults
- clinical practice
- chronic kidney disease
- study protocol
- chemotherapy induced
- patient reported outcomes
- patient reported
- lymph node metastasis